Provided by Tiger Fintech (Singapore) Pte. Ltd.

Skye Bioscience Inc.

1.57
+0.13509.41%
Post-market: 1.55-0.0200-1.27%19:58 EDT
Volume:568.35K
Turnover:848.85K
Market Cap:48.63M
PE:-2.15
High:1.58
Open:1.40
Low:1.36
Close:1.44
Loading ...
Jun 10, 2024

Major Issues Report

Form 8-K - Current report
May 16, 2024

Correspondence

Form CORRESP - Correspondence
May 16, 2024

Correspondence

Form CORRESP - Correspondence
May 15, 2024

Correspondence

Form CORRESP - Correspondence
May 15, 2024

Correspondence

Form CORRESP - Correspondence
May 10, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 10, 2024

Correspondence

Form CORRESP - Correspondence
Apr 10, 2024

Correspondence

Form CORRESP - Correspondence
Apr 10, 2024

Correspondence

Form CORRESP - Correspondence
Apr 04, 2024

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Apr 03, 2024

Major Issues Report

Form 8-K - Current report
Mar 27, 2024

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Mar 22, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 13, 2024

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Mar 13, 2024

Major Issues Report

Form 8-K - Current report
Mar 04, 2024

Major Issues Report

Form 8-K - Current report
Feb 12, 2024

Major Issues Report

Form 8-K - Current report
Feb 08, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 03, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Jan 31, 2024

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]